Caryl E Sortwell1, Mallory L Hacker2, David Luke Fischer3, Peter E Konrad4, Thomas L Davis2, Joseph S Neimat4, Lily Wang5, Yanna Song5, Zach R Mattingly3, Allyson Cole-Strauss3, Jack W Lipton6, P David Charles2. 1. Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA; Hauenstein Neuroscience Center, Mercy Health Saint Mary's, Grand Rapids, MI, USA. Electronic address: sortwell@msu.edu. 2. Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. 4. Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. 6. Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA; Hauenstein Neuroscience Center, Mercy Health Saint Mary's, Grand Rapids, MI, USA.
Abstract
INTRODUCTION: The efficacy of pharmacotherapy and deep brain stimulation of the subthalamic nucleus in treating Parkinson's disease motor symptoms is highly variable and may be influenced by patient genotype. The relatively common (prevalence about one in three) and protein-altering rs6265 single nucleotide polymorphism (C > T) in the gene BDNF has been associated with different clinical outcomes with levodopa. OBJECTIVE: We sought to replicate this reported association in early-stage Parkinson's disease subjects and to examine whether a difference in clinical outcomes was present with subthalamic nucleus deep brain stimulation. MATERIALS AND METHODS: Fifteen deep brain stimulation and 13 medical therapy subjects were followed for 24 months as part of the Vanderbilt DBS in Early Stage PD clinical trial (NCT00282152, FDA IDE #G050016). Primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) and Parkinson's Disease Questionnaire-39. RESULTS: Outcomes with drug therapy in subjects carrying the rs6265 T allele were significantly worse following 12 months of treatment compared to C/C subjects (UPDRS: +20 points, p = 0.019; PDQ-39: +16 points, p = 0.018). In contrast, rs6265 genotype had no effect on overall motor response to subthalamic nucleus deep brain stimulation at any time point; further, rs6265 C/C subjects treated with stimulation were associated with worse UPDRS part II scores at 24 months compared to medical therapy. CONCLUSIONS: Genotyping for the rs6265 polymorphism may be useful for predicting long-term response to drug therapy and counseling Parkinson's disease patients regarding whether to consider earlier subthalamic nucleus deep brain stimulation. Validation in a larger cohort of early-stage Parkinson's disease subjects is warranted.
INTRODUCTION: The efficacy of pharmacotherapy and deep brain stimulation of the subthalamic nucleus in treating Parkinson's disease motor symptoms is highly variable and may be influenced by patient genotype. The relatively common (prevalence about one in three) and protein-altering rs6265 single nucleotide polymorphism (C > T) in the gene BDNF has been associated with different clinical outcomes with levodopa. OBJECTIVE: We sought to replicate this reported association in early-stage Parkinson's disease subjects and to examine whether a difference in clinical outcomes was present with subthalamic nucleus deep brain stimulation. MATERIALS AND METHODS: Fifteen deep brain stimulation and 13 medical therapy subjects were followed for 24 months as part of the Vanderbilt DBS in Early Stage PD clinical trial (NCT00282152, FDA IDE #G050016). Primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) and Parkinson's Disease Questionnaire-39. RESULTS: Outcomes with drug therapy in subjects carrying the rs6265 T allele were significantly worse following 12 months of treatment compared to C/C subjects (UPDRS: +20 points, p = 0.019; PDQ-39: +16 points, p = 0.018). In contrast, rs6265 genotype had no effect on overall motor response to subthalamic nucleus deep brain stimulation at any time point; further, rs6265 C/C subjects treated with stimulation were associated with worse UPDRS part II scores at 24 months compared to medical therapy. CONCLUSIONS: Genotyping for the rs6265 polymorphism may be useful for predicting long-term response to drug therapy and counseling Parkinson's disease patients regarding whether to consider earlier subthalamic nucleus deep brain stimulation. Validation in a larger cohort of early-stage Parkinson's disease subjects is warranted.
Authors: José A G Agúndez; Elena García-Martín; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez Journal: Expert Opin Drug Metab Toxicol Date: 2013-04-09 Impact factor: 4.481
Authors: Alberto J Espay; Michael A Schwarzschild; Caroline M Tanner; Hubert H Fernandez; David K Simon; James B Leverenz; Aristide Merola; Alice Chen-Plotkin; Patrik Brundin; Marcelo A Kauffman; Roberto Erro; Karl Kieburtz; Daniel Woo; Eric A Macklin; David G Standaert; Anthony E Lang Journal: Mov Disord Date: 2017-02-24 Impact factor: 10.338
Authors: Anne L Spieles-Engemann; Kathy Steece-Collier; Michael M Behbehani; Timothy J Collier; Susan L Wohlgenant; Christopher J Kemp; Allyson Cole-Strauss; Nathan D Levine; Sara E Gombash; Valerie B Thompson; Jack W Lipton; Caryl E Sortwell Journal: J Parkinsons Dis Date: 2011 Impact factor: 5.568
Authors: D Luke Fischer; Peggy Auinger; John L Goudreau; Allyson Cole-Strauss; Karl Kieburtz; Jordan J Elm; Mallory L Hacker; P David Charles; Jack W Lipton; Barbara A Pickut; Caryl E Sortwell Journal: Neurotherapeutics Date: 2020-11-19 Impact factor: 7.620
Authors: Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger Journal: Cell Date: 2003-01-24 Impact factor: 41.582
Authors: Zhe-Yu Chen; Paresh D Patel; Gayatree Sant; Chui-Xiang Meng; Kenneth K Teng; Barbara L Hempstead; Francis S Lee Journal: J Neurosci Date: 2004-05-05 Impact factor: 6.167
Authors: Julius Kricheldorff; Katharina Göke; Maximilian Kiebs; Florian H Kasten; Christoph S Herrmann; Karsten Witt; Rene Hurlemann Journal: Brain Sci Date: 2022-07-15